If the cancer has advanced, often you've missed your window
Each year, more than 4,500 New Zealand men learn they have prostate cancer, and over 700 will die from it — not because the disease is new, but because a population is aging and a culture of avoidance persists. A simple blood test exists that can catch the illness before it speaks, yet no national screening programme has been funded, and the silence of early-stage disease continues to cost lives. This is a story as old as medicine itself: the gap between what is known and what is done.
- Over 700 New Zealand men die from prostate cancer annually, in a disease that often gives no warning until it is too late to cure.
- The cruel irony is that early prostate cancer is entirely silent — by the time a man feels something is wrong, his window for curative treatment may already have closed.
- High-risk groups — Māori men, men of African descent, those with BRCA2 mutations or two or more affected relatives — face elevated danger, yet many have no idea screening timelines should begin years earlier for them.
- A member's bill sought to establish a dedicated national screening programme, but the 2026 Budget passed without funding it, despite evidence that early treatment is far cheaper than managing advanced disease.
- The remaining barrier is cultural: many men avoid doctors out of fear of bad news, inverting the very logic of self-preservation that should drive them toward a straightforward blood test.
Every year in New Zealand, roughly 4,500 men are diagnosed with prostate cancer, and more than 700 will not survive it. The disease will touch one in eight men in their lifetime — a burden that urological surgeon Dr Jim Duthie says will only grow as the population ages, since age is the primary risk factor.
The disease's most dangerous quality is its silence. Early prostate cancer produces no symptoms. By the time a man notices frequent urination, bone pain, or blood in the urine, the cancer may have advanced beyond the reach of a cure. PSA testing — a simple blood test — can detect problems before the body raises any alarm. Duthie is direct: once symptoms appear, the window for curative treatment is often already closed.
Screening should begin at 55 for most men, but family history changes everything. A man with two or more affected close relatives should begin testing a decade before the youngest relative's age at diagnosis. Māori men, men of African descent, and those carrying the BRCA2 gene mutation all carry elevated risk. Yet most men diagnosed have no family history at all — the disease is simply common enough to reach millions.
Lifestyle offers modest protection. Smoking, heavy drinking, and obesity each raise risk slightly, while a heart-healthy diet and regular exercise benefit men already living with slower-growing cancers. Treatment options include surgery, radiation, active surveillance, and therapies for advanced disease — though several effective drugs remain unfunded in New Zealand.
A member's bill proposed a national prostate cancer screening programme, but the 2026 Budget did not fund it. Duthie calls this a missed opportunity on both humanitarian and economic grounds: early treatment costs a fraction of managing advanced disease. The final obstacle is cultural — men who avoid doctors out of fear are, in effect, trading a manageable problem for a potential crisis. The choice, Duthie argues, is not between health and illness, but between early action and late consequence.
Every year in New Zealand, roughly 4,500 men receive a prostate cancer diagnosis. More than 700 of them will not survive it. The disease will touch one in eight men at some point in their lives—a statistic that has gained fresh urgency since actor Jeremy Clarkson went public with his own aggressive diagnosis, documented in his television series, and subsequently announced he had entered remission after treatment.
Dr Jim Duthie, a urological surgeon and medical adviser to the Prostate Cancer Foundation of New Zealand, frames the challenge plainly: the disease is becoming more common not because of any new threat, but because New Zealand's population is aging. Men are living longer, and age remains the primary risk factor. The longer a man lives, the more likely prostate cancer will develop. This demographic reality means the burden on the health system will only grow without intervention.
The cruelest aspect of early prostate cancer is its silence. Men in the earliest stages typically feel nothing wrong. By the time symptoms emerge—frequent urination, pain during urination, blood in the urine, bone pain, unexplained weight loss—the disease may have progressed beyond the point where cure is possible. This is why Duthie emphasizes that prostate-specific antigen testing, or PSA, matters so much. A simple blood test can flag problems before the body sends distress signals. "If the cancer has advanced to where it's causing bladder symptoms or bone pain, often that means you've missed your window," Duthie explains. Early detection transforms outcomes; late detection often does not.
The screening timeline matters. Men should begin regular PSA testing at 55, when the disease becomes more common. But family history changes the calculus entirely. If two or more close relatives have had prostate cancer, testing should start a decade earlier than the youngest affected relative's age at diagnosis. A man whose brother was diagnosed at 47 should begin screening at 37. Certain populations carry elevated risk: Māori men, men of African descent, and those carrying the BRCA2 gene mutation—the same genetic marker linked to breast cancer in women. For men with a strong family history, personal risk can reach 40 percent. Yet most men diagnosed have no family history at all; they are simply unlucky in a disease that is common enough to touch millions.
Lifestyle offers some protection, though modest. Heavy drinking, smoking, and obesity all increase risk slightly. More importantly, for men already diagnosed with less aggressive forms, a heart-healthy life—leafy greens, cruciferous vegetables like broccoli and cabbage, exercise at least four times weekly for thirty minutes—can extend both lifespan and quality of life. Duthie notes that many older men with slow-growing prostate cancers will ultimately die of heart disease instead, making cardiovascular health a practical priority.
New Zealand offers multiple treatment pathways: surgery, radiation, active surveillance for slower-growing cancers, and for advanced disease, chemotherapy, hormone therapy, or immunotherapy. Each approach carries trade-offs that must be tailored to the individual. Yet several effective drugs remain unfunded in New Zealand, limiting options for some patients. Last year, a member's bill proposed establishing a dedicated prostate cancer screening programme. The 2026 Budget, announced in May, did not allocate funding for it. Duthie calls this disappointing, not merely on humanitarian grounds but on economic ones: early treatment costs far less than managing advanced disease, and the investment would pay for itself.
The final barrier is cultural. Some men wear their avoidance of doctors like a badge of honor, Duthie observes—a refusal rooted in fear. The prospect of bad news keeps them away. But this logic inverts the actual risk. Regular checkups, like car maintenance, catch problems when they remain treatable and curable. "It's much simpler treatment and it's better for everybody," Duthie says. The choice is not between health and illness, but between early intervention and late crisis.
Citações Notáveis
If the cancer has progressed to where it's causing bladder symptoms or bone pain, often that's an indicator you've missed your opportunity for a cure— Dr Jim Duthie, urological surgeon
It's the same as car maintenance. It's foolish to wait until it falls over. Get in early and things are treatable, curable and have much better outcomes— Dr Jim Duthie
A Conversa do Hearth Outra perspectiva sobre a história
Why does age matter so much with prostate cancer? It seems like it should be random.
It's not random at all. The longer cells divide and replicate, the more chances they have to mutate. Prostate cells keep dividing throughout a man's life. By 55 or 60, those cells have had decades to accumulate damage. It's a numbers game.
So if I'm 40 and have no family history, I don't need to worry?
Not yet. But if your father or uncle had it, that changes everything. You'd want to start testing at least ten years before they were diagnosed. The genes that predispose you to this are real.
What's the actual difference between a PSA test and a digital rectal exam?
The PSA is a blood test—it measures a protein the prostate makes. It's not a cancer diagnosis by itself; it just tells you whether something might be wrong. The rectal exam is physical. It gives limited extra information, and honestly, many men skip it without losing much.
If I get tested and my PSA is high, what happens next?
You'd likely get an ultrasound or a biopsy to see if cancer is actually present. But here's the thing: many men have elevated PSA from benign prostate enlargement, not cancer. The test flags risk, not certainty.
You mentioned diet helping men with recurring cancer. How much does that actually matter?
The evidence is real. Men who eat lots of cruciferous vegetables and exercise regularly live longer and feel better than those who don't. It won't cure advanced cancer, but it extends life and quality. That's not nothing.
Why hasn't New Zealand funded a screening programme if early detection saves money?
That's the frustrating part. The economics are clear—treating early cancer costs less than treating late cancer. But screening programmes require upfront investment and political will. It didn't make the budget priorities this year.